European Respiratory Journal

Papers
(The H4-Index of European Respiratory Journal is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge561
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension483
The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19363
A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis359
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline359
ERS/ATS technical standard on interpretive strategies for routine lung function tests356
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset313
ERS statement on chronic thromboembolic pulmonary hypertension282
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial278
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study276
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?267
Pulmonary embolism in patients with COVID-19 pneumonia266
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial257
COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force255
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients251
ERS clinical practice guidelines on treatment of sarcoidosis245
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes232
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19224
COVID-19 and pneumothorax: a multicentre retrospective case series220
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary215
COVID-19 and COPD213
Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation201
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases198
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study189
Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia184
Trends in worldwide asthma prevalence170
Pathogenesis of COVID-19-induced ARDS: implications for an ageing population160
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome155
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry154
The potential impact of COVID-19-related disruption on tuberculosis burden149
Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study146
Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication144
Patient-reported outcome measures after COVID-19: a prospective cohort study143
The impact of COVID-19 on patients with asthma143
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline143
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma143
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection141
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors136
Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China135
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update131
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study130
Thrombosis and COVID-19 pneumonia: the clot thickens!129
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue123
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation123
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension118
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life118
Endothelial cells in the pathogenesis of pulmonary arterial hypertension115
Methotrexate and rheumatoid arthritis associated interstitial lung disease114
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure113
Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study111
Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study109
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis109
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection109
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years107
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies107
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase106
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab104
Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital103
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)102
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry101
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics96
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis95
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study94
Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up93
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences93
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis93
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial93
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator92
Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS92
Effect of asthma and asthma medication on the prognosis of patients with COVID-1989
European Respiratory Society guidelines for the diagnosis of asthma in adults88
Social stigma in the time of coronavirus disease 201986
Between inflammation and thrombosis: endothelial cells in COVID-1986
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients86
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study85
On tuberculosis and COVID-19 co-infection84
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry83
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis82
European Respiratory Society statement on long COVID follow-up82
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial81
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health80
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure80
0.050858020782471